NLS Financial Statements From 2010 to 2025

NLSP Stock  USD 1.55  0.03  1.90%   
NLS Pharmaceutics financial statements provide useful quarterly and yearly information to potential NLS Pharmaceutics AG investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NLS Pharmaceutics financial statements helps investors assess NLS Pharmaceutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NLS Pharmaceutics' valuation are summarized below:
Market Capitalization
6.3 M
Earnings Share
(6.74)
There are currently one hundred twenty fundamental ratios for NLS Pharmaceutics that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check NLS Pharmaceutics' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to drop to about 660 M. In addition to that, Enterprise Value is likely to drop to about 908 M
Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 K, Interest Expense of 124.1 K or Selling General Administrative of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.
  
Check out the analysis of NLS Pharmaceutics Correlation against competitors.

NLS Pharmaceutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.3 M2.1 M2.7 M
Pretty Stable
Short and Long Term Debt Total1.4 M1.5 M5.5 M
Slightly volatile
Other Current LiabilitiesM1.9 M779.7 K
Slightly volatile
Total Current Liabilities9.6 M9.1 M3.4 M
Slightly volatile
Other Liabilities1.9 M3.2 M1.3 M
Slightly volatile
Accounts Payable2.7 M5.3 M1.8 M
Slightly volatile
Cash980.7 KM2.2 M
Very volatile
Non Current Assets Total20.2 K21.2 K102.3 K
Pretty Stable
Non Currrent Assets Other14.4 K15.2 K87 K
Pretty Stable
Other Assets0.860.930.3 K
Very volatile
Long Term Debt268 K282.1 KM
Slightly volatile
Cash And Short Term Investments980.7 KM2.2 M
Very volatile
Net Receivables9.1 K9.6 K60.1 K
Slightly volatile
Common Stock Total Equity151.8 K166.9 K137.8 K
Slightly volatile
Common Stock Shares Outstanding46.1 M43.9 M17.8 M
Slightly volatile
Liabilities And Stockholders Equity3.3 M2.1 M2.7 M
Pretty Stable
Non Current Liabilities Total3.4 M2.5 M6.2 M
Slightly volatile
Other Current Assets1.1 M1.1 M279.1 K
Slightly volatile
Other Stockholder Equity35.5 M70.1 M24.4 M
Slightly volatile
Total Liabilities6.6 M9.6 MM
Slightly volatile
Total Current Assets3.1 M2.1 M2.6 M
Pretty Stable
Common Stock885.6 K843.4 K307.9 K
Slightly volatile
Short and Long Term Debt1.3 M1.9 M1.1 M
Slightly volatile
Capital Stock885.6 K843.4 K310.5 K
Slightly volatile
Short Term Debt1.8 M1.9 M157.2 M
Pretty Stable
Deferred Long Term Liabilities663.9 K1.1 M508.9 K
Slightly volatile
Property Plant Equipment23.6 K26.6 K29 K
Slightly volatile

NLS Pharmaceutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense124.1 K130.6 K613.4 K
Slightly volatile
Selling General Administrative7.1 M6.8 M2.3 M
Slightly volatile
Other Operating Expenses8.6 M13.6 M7.3 M
Slightly volatile
Research Development4.5 M6.8 M4.4 M
Pretty Stable
Total Operating Expenses8.6 M13.6 M7.3 M
Slightly volatile
Selling And Marketing Expenses9.8 K10.3 K2.5 M
Pretty Stable
Cost Of Revenue12.1 K13.1 K10.5 K
Slightly volatile

NLS Pharmaceutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.8 M10.3 M2.8 M
Slightly volatile
Total Cash From Financing Activities1.8 M1.9 M6.1 M
Very volatile
End Period Cash Flow980.7 KM2.2 M
Very volatile
Depreciation9.8 K10.3 K4.5 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.6 M1.8 M1.4 M
Slightly volatile
Capex To Depreciation4.0E-44.0E-42.9523
Slightly volatile
Payables Turnover0.00480.00280.0053
Slightly volatile
Cash Per Share0.02570.0272.8268
Very volatile
Days Payables Outstanding76.6 K133.4 K74.5 K
Slightly volatile
Income Quality0.520.720.7173
Pretty Stable
Current Ratio0.20.211.5192
Slightly volatile
Average Receivables29.8 K50.5 K32.9 K
Slightly volatile
Interest Debt Per Share0.05090.05362.8 K
Very volatile
Debt To Assets0.971.025.4551
Very volatile
Days Of Payables Outstanding76.6 K133.4 K74.5 K
Slightly volatile
Ebt Per Ebit1.31.191.179
Very volatile
Quick Ratio0.20.211.5218
Slightly volatile
Cash Ratio0.09690.11.434
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.9836
Slightly volatile
Debt Ratio0.971.025.4551
Very volatile

NLS Pharmaceutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap660 M808.1 MB
Slightly volatile
Enterprise Value908 MB1.1 B
Slightly volatile

NLS Fundamental Market Drivers

Cash And Short Term Investments897.7 K

NLS Upcoming Events

3rd of May 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NLS Pharmaceutics investors may analyze each financial statement separately, they are all interrelated. The changes in NLS Pharmaceutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on NLS Pharmaceutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue2.9 B1.8 B
Cost Of Revenue13.1 K12.1 K

Pair Trading with NLS Pharmaceutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NLS Pharmaceutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will appreciate offsetting losses from the drop in the long position's value.

Moving against NLS Stock

  0.58DVAX Dynavax TechnologiesPairCorr
The ability to find closely correlated positions to NLS Pharmaceutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NLS Pharmaceutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NLS Pharmaceutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NLS Pharmaceutics AG to buy it.
The correlation of NLS Pharmaceutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NLS Pharmaceutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NLS Pharmaceutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NLS Pharmaceutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.